# Christine Borowski

> Christine Borowski is a Series B investor at Access Biotechnology backing Biotechnology. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Access Biotechnology](https://shizune.co/investors/profile/access-biotechnology)
- Location: New York, United States
- Total investments: 3
- Last investment: Oct 2025
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/christine-borowski-214172153/

Christine Borowski is a Series B investor at Access Biotechnology in New York focused on Biotechnology and Medical. Christine Borowski is the Senior Associate at Access Biotechnology.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Medical | 1 | 33% |
| Health Care | 1 | 33% |
| Life Science | 1 | 33% |
| Pharmaceutical | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 67% |
| Series C | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Denmark | 1 | 33% |
| United States | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Hemab | Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threateningcomplications. | $157M | Series C | Oct 27, 2025 |  |
| Santa Ana Bio | Santa Ana Bio is a biotechnology company that leverages deep cell profiling technologies to design precision biologics in the autoimmune space. The company was founded in 2021 and is headquartered in Alameda, California. | $125M | Series B | Jun 13, 2024 |  |
| Hemab | Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threateningcomplications. | $135M | Series B | Feb 21, 2023 |  |

3 of 3 investments shown.

## Co-investors
- [Avoro Ventures](https://shizune.co/investors/profile/avoro-ventures) — VC Fund, 2 deals together
- [Deep Track Capital](https://shizune.co/investors/profile/deep-track-capital) — VC Fund, 2 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 2 deals together
- [HealthCap](https://shizune.co/investors/profile/healthcap) — VC Fund, 2 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 2 deals together
- [Maj Invest Equity](https://shizune.co/investors/profile/maj-invest-equity) — VC Fund, 2 deals together

## About Access Biotechnology

VC Fund · New York, United States

Access Biotechnology is the life science investment arm of Access Industries. They invest in transformative therapies for conditions with high unmet needs and that have the potential to meaningfully impact human health. They invest in both private and public biopharma companies across therapeutic areas, modalities, and development stages – fromdiscovery-stage technology platforms to late-stage clinical programs.The company is based in New York.

4 contacts available at Access Biotechnology.

| Name | Title | Profile |
| --- | --- | --- |
| Christine Borowski | Senior Associate | https://shizune.co/investors/profile/christine-borowski |
| Dan Becker | Principal | https://shizune.co/investors/profile/dan-becker |
| Jeffrey Ives | Advisor | https://shizune.co/investors/profile/jeffrey-ives |
| Liam Ratcliffe | Head of Biotechnology | https://shizune.co/investors/profile/liam-ratcliffe |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Christine Borowski invest in?

Christine Borowski invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series C stage. Most of the 3 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Christine Borowski last invest?

The most recent investment recorded for Christine Borowski closed in Oct 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co